KASID
Search
- Page Path
- HOME > Search
Original Articles
- Real-world use of biologics during the first year of treatment for newly diagnosed Crohn’s disease in Japan: a claims analysis from 2010 to 2021
- Jun Miyoshi, Annabelle Yoon, Minoru Matsuura, Tadakazu Hisamatsu
- Received June 5, 2024 Accepted October 5, 2024 Published online January 23, 2025
- DOI: https://doi.org/10.5217/ir.2024.00082 [Epub ahead of print]
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Background/Aims
Crohn’s disease (CD) leads to bowel damage and disability if suboptimally treated. We investigated firstyear treatment decisions and real-world use of biologics in patients with CD in Japan.
Methods
In this retrospective observational study (2010–2021) from the JMDC claims database, patients with a new diagnosis of CD (no CD claims record within 12 months before index) who received ≥ 1 pre-defined treatment were grouped by use of biologics and systemic corticosteroids (SCS) within the first year of diagnosis.
Results
Of 823 patients included, 470 (57.1%) were prescribed biologics and 353 (42.9%) were not; 77.6% were male, 75.7% had adult-onset CD, and median age was 24 years. Patients prescribed biologics were younger (median: 23 years vs. 28 years) and more had perianal lesions (43.0% vs. 22.9%) than those not prescribed biologics; 64.9% (95% confidence interval, 60.4%–69.2%) received a top-down treatment approach (no SCS before biologics). Factors significantly associated with a top-down treatment approach were male sex, perianal lesions, no use of immunomodulators, and use of anti-tumor necrosis factor therapies. The proportion of patients receiving SCS before biologics (step-up approach) increased after 2018, with a shift from prednisolone to budesonide from 2016. Persistence with first biologics decreased over time, with no differences between biologic types.
Conclusions
Use of biologics for treatment of CD within the first year of diagnosis in Japan has remained stable over the past decade. However, there was a shift to a step-up treatment approach, with an increase in use of SCS before biologics over time.
- 872 View
- 127 Download
- IBD
- Changes in the clinical course and prognosis of ulcerative colitis in Chinese populations: a retrospective cohort study
- Xinyu Liu, Qingfan Yang, Na Diao, Jian Tang, Zicheng Huang, Xiang Gao, Kang Chao
- Intest Res 2024;22(3):357-368. Published online May 7, 2024
- DOI: https://doi.org/10.5217/ir.2023.00106
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Data on the natural course of Chinese patients with ulcerative colitis (UC) was lacking. This study aimed to evaluate the natural history and prognosis of patients with UC in the past 15 years in China.
Methods
This cohort study included patients with UC in a tertiary hospital in southern China from 2007 to 2021 (cohort I: 2007–2011, cohort II: 2012–2016, cohort III: 2017–2021). Patients’ clinical characteristics and natural history were analyzed retrospectively.
Results
Of 1,139 included patients, 683 patients presented with proctitis or left-sided colitis at diagnosis and 38.5% of them (263/683) developed proximal disease extension. Fifty-eight percent of patients experienced relapse, chronic continuous and intermittent active course. Five patients (0.4%) developed colorectal tumors/dysplasia. The overall surgery rate was 8.6%, and the rates were 14.2%, 7.8%, and 8.0% in the 3 cohorts, respectively (P= 0.059). Average time from diagnosis to surgery decreased from cohorts I to III (144 months vs. 36 months, P< 0.001), so did the use of glucocorticoids (58.2% vs. 43.5%, P< 0.001) and immunosuppressants (14.1% vs. 13.4%, P= 0.016), and days of hospitalization (13 days vs. 9 days, P< 0.001). Biologics were used more frequently during the first year (0.8%, 2.1%, and 13.7% for cohorts I to III, respectively; P< 0.001). The rate of mucosal healing increased over time.
Conclusions
In Chinese UC patients, one-third of patients experienced proximal disease extension. The rates of malignancy and mortality were low. More biologics were used, while use of immunosuppressants and glucocorticoids were reduced over time. Early biologics use seemed to promote mucosal healing, but the rate of colectomy has not dramatically decreased.
- 2,508 View
- 176 Download
- IBD
- Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab
- Hisashi Shiga, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Yoichi Kakuta, Yoshitaka Kinouchi, Atsushi Masamune
- Intest Res 2024;22(3):378-386. Published online March 26, 2024
- DOI: https://doi.org/10.5217/ir.2023.00203
-
Abstract
PDFPubReaderePub
- Background/Aims
Vedolizumab (VDZ) is a gut-selective agent with a favorable safety profile. We aimed to assess the feasibility of elective switch from other advanced therapies to VDZ and subsequent live-attenuated vaccination while continuing VDZ in patients with inflammatory bowel diseases (IBD).
Methods
We measured antibody titers specific for measles, rubella, mumps, and varicella viruses in IBD patients under immunosuppressive therapy. Those with negative titers and without vaccination history were judged unimmunized. Patients were administered vaccines while continuing VDZ or switched to VDZ if receiving other advanced therapies and then administered vaccines. Co-primary outcomes were the rate of maintaining disease severity after vaccination and the rate without vaccine-induced infection.
Results
Among 107 unimmunized patients, 37 agreed to receive live-attenuated vaccines while continuing VDZ (17 patients) or after switching to VDZ (20 patients). In the 20 patients who electively switched to VDZ, disease severity was maintained except for 1 patient who developed intestinal infection. After 54 weeks, 18 patients (90%) continued to receive VDZ, excluding 2 patients who reverted to their originally administered biologics. In all 37 patients administered live-attenuated vaccines under VDZ treatment, disease severity was maintained after vaccination. Antibody titers became positive or equivocal in 34 patients (91.9%). There were no cases of vaccine-induced infection during a median observation period of 121 weeks.
Conclusions
While live-attenuated vaccines are contraindicated under immunosuppressive therapy, they may be safely administered while receiving VDZ immunotherapy. Switching from other advanced therapies to VDZ and subsequently receiving live-attenuated vaccines may be a safe alternative in unimmunized patients. -
Citations
Citations to this article as recorded by
- Live Typhoid and Yellow Fever Vaccines Administered to a Patient With Ulcerative Colitis on Vedolizumab
Yash Hegde, Mary S. Hayney, Freddy Caldera
ACG Case Reports Journal.2024; 11(10): e01507. CrossRef
- Live Typhoid and Yellow Fever Vaccines Administered to a Patient With Ulcerative Colitis on Vedolizumab
- 2,928 View
- 300 Download
- 1 Web of Science
- 1 Crossref
Review
- IBD
- The practice of fecal microbiota transplantation in inflammatory bowel disease
- Umang Arora, Saurabh Kedia, Vineet Ahuja
- Intest Res 2024;22(1):44-64. Published online November 21, 2023
- DOI: https://doi.org/10.5217/ir.2023.00085
-
Abstract
PDFPubReaderePub
- Current evidence posits a central role for gut microbiota and the metabolome in the pathogenesis and progression of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) has been established as a means to manipulate this microbiome safely and sustainably. Several aspects of the technical improvement including pretreatment with antibiotics, use of frozen stool samples as well as short donor-to-recipient time are proposed to improve its response rates. Its efficacy in ulcerative colitis has been proven in clinical trials while data is emerging for Crohn’s disease. This review describes briefly the biology behind FMT, the available evidence for its use in IBD, and the host, recipient and procedural factors which determine the clinical outcomes.
-
Citations
Citations to this article as recorded by- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
Shuna Hou, Jiachen Yu, Yongshuang Li, Duoyi Zhao, Zhiyu Zhang
Advanced Science.2025;[Epub] CrossRef - Gut Microbial Targets in Inflammatory Bowel Disease: Current Position and Future Developments
Naveen Sivakumar, Ashwin Krishnamoorthy, Harshita Ryali, Ramesh P. Arasaradnam
Biomedicines.2025; 13(3): 716. CrossRef - Medical management of acute severe ulcerative colitis in the hospitalized patient
Loren G Rabinowitz, Ajay Gade, Joseph D. Feuerstein
Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef - Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
The Korean Journal of Internal Medicine.2024; 39(5): 783. CrossRef - Microbiome-based therapeutics for Parkinson's disease
Adam M. Hamilton, Ian N. Krout, Alexandria C. White, Timothy R. Sampson
Neurotherapeutics.2024; 21(6): e00462. CrossRef
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
- 5,742 View
- 342 Download
- 5 Crossref
Original Article
- IBD
- Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis
- Taku Kobayashi, Eri Udagawa, Lisa Hirose, Toshifumi Hibi
- Intest Res 2023;21(2):205-215. Published online December 15, 2022
- DOI: https://doi.org/10.5217/ir.2021.00164
-
Abstract
PDFPubReaderePub
- Background/Aims
Risks of long-term steroid use in patients with ulcerative colitis (UC) outweigh the benefits, thus dosing should be tapered once a response is achieved. Colonoscopy is a key technique for assessing disease severity and optimizing treatment involving steroids. This retrospective longitudinal cohort study of patients with UC explored factors associated with the duration of systemic steroid use.
Methods
The Japan Medical Data Center database, an employer-based insurance claims database, was used to select individuals initiating prednisolone, with a prescription issued between January 1, 2010, and January 31, 2018. The study included adults with a confirmed diagnosis of UC, who had received ≥1 year of continuous treatment with 5-aminosalicylic acid, biologics, or thiopurine. Factors associated with prednisolone duration were assessed using a multivariate regression model.
Results
Median duration of prednisolone treatment was 98 days, and colonoscopy was performed ≤1 month before or at the first prescription of prednisolone (index date) in 32.8% of patients (607/1,853). Shorter durations of prednisolone treatment were associated with colonoscopy ≤1 month before or at the index date and higher prednisolone dose at index date, with incidence rate ratios (IRRs) of 0.776 (95% confidence interval [CI], 0.682–0.884; P<0.001) and 0.998 (95% CI, 0.996–1.000; P=0.018), respectively. Charlson Comorbidity Index scores of 1 and ≥2 predicted longer prednisolone treatment (IRR, 1.332; 95% CI, 1.174–1.511; P<0.001 and IRR, 1.599; 95% CI, 1.357–1.885; P<0.001, respectively).
Conclusions
Performing colonoscopy before or at the time of initiating steroid was associated with a shorter duration of steroid use in patients with UC. -
Citations
Citations to this article as recorded by- Quercus infectoria galls mitigates colitis in mice through alleviating mucosal barrier impairment and suppressing inflammatory factors
Yan Ding, Jiao-Jiao Bai, Sabahat Ablimit, Muyassar Yasen, Arfidin Anwar, Kudelaidi Kuerban, Mubarak Iminjan, Guo-Qiang Zhang
Journal of Ethnopharmacology.2025; 343: 119487. CrossRef
- Quercus infectoria galls mitigates colitis in mice through alleviating mucosal barrier impairment and suppressing inflammatory factors
- 3,706 View
- 359 Download
- 2 Web of Science
- 1 Crossref
Review
- Functional bowel disorder
- An Asian perspective on irritable bowel syndrome
- Kee Wook Jung, Seung-Jae Myung
- Intest Res 2023;21(2):189-195. Published online May 31, 2022
- DOI: https://doi.org/10.5217/ir.2021.00136
-
Abstract
PDFPubReaderePub
- Irritable bowel syndrome (IBS) is a prevalent chronic disorder, and its epidemiology depends on the diagnostic criteria used. Recently, the Rome IV criteria for IBS were published by changing the frequency of abdominal pain and excluding abdominal discomfort from the previously used Rome III criteria. However, the recent Asian consensus on IBS recommends the inclusion of abdominal discomfort and abdominal pain as diagnostic criteria. The low fermentable oligo-, di-, mono-saccharides, and polyols (FODMAP) diet has been proven to be effective in Western patients. Moreover, recent well-designed studies reported its effectiveness and the microbial changes after implementing it in Asian patients with IBS. However, traditional Korean foods including kimchi, one of representative FODMAP-rich food, exhibited a poor correlation with the food-related symptoms of IBS. Therefore, the low FODMAP diet protocol should be cautiously applied to IBS patients, especially to Korean patients with IBS. In Asian countries, there are lots of traditional herbal medicines and treatments for IBS; however, these studies have limitations including the heterogeneity of herbal mixtures and relatively small sample size. Therefore, well-designed studies based on large samples are required to validate complementary and alternative medicine in the treatment of Asian patients with IBS.
-
Citations
Citations to this article as recorded by- The Role of Diet in the Management of Irritable Bowel Syndrome: A Comprehensive Review
Maleesha Jayasinghe , Vinuri Karunanayake, Ali Mohtashim, Dilushini Caldera , Piyalka Mendis , Omesh Prathiraja, Fatemeh Rashidi, John A Damianos
Cureus.2024;[Epub] CrossRef - Downregulated APOD and FCGR2A correlates with immune infiltration and lipid-induced symptoms of irritable bowel syndrome
Yamei Ran, Kangqi Wu, Chenglin Hu, Renzheng Liang, Li Zhang, Juan Xiao, Yongmei Peng, Wenjing Sun
Scientific Reports.2023;[Epub] CrossRef - Technical Feasibility of Quantitative Measurement of Various Degrees of Small Bowel Motility Using Cine Magnetic Resonance Imaging
Ji Young Choi, Jihye Yun, Subin Heo, Dong Wook Kim, Sang Hyun Choi, Jiyoung Yoon, Kyuwon Kim, Kee Wook Jung, Seung-Jae Myung
Korean Journal of Radiology.2023; 24(11): 1093. CrossRef - Letter to the Editor: Survey-Based Analysis of Clinical Treatment Status of Irritable Bowel Syndrome in Korea: Suggestions for Future Research
Ji Young Chang
Journal of Korean Medical Science.2023;[Epub] CrossRef - Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis
Annie Tremblay, Xiaoyu Xu, James Colee, Thomas A. Tompkins, Sylvie Binda
Gastroenterology Insights.2023; 14(4): 491. CrossRef - Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Kwang Woo Kim
Gut and Liver.2023; 17(6): 954. CrossRef
- The Role of Diet in the Management of Irritable Bowel Syndrome: A Comprehensive Review
- 5,967 View
- 626 Download
- 6 Web of Science
- 6 Crossref
Original Articles
- IBD
- One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
- Yuichi Matsuno, Takehiro Torisu, Junji Umeno, Hiroki Shibata, Atsushi Hirano, Yuta Fuyuno, Yasuharu Okamoto, Shin Fujioka, Keisuke Kawasaki, Tomohiko Moriyama, Tomohiro Nagasue, Keizo Zeze, Yoichiro Hirakawa, Shinichiro Kawatoko, Yutaka Koga, Yoshinao Oda, Motohiro Esaki, Takanari Kitazono
- Intest Res 2022;20(2):260-268. Published online April 29, 2022
- DOI: https://doi.org/10.5217/ir.2021.00124
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Recent studies suggested a favorable effect of indigo naturalis (IN) in inducing remission for refractory ulcerative colitis (UC), however, the maintenance effect of IN for patients with UC remains unknown. Therefore, we conducted a prospective uncontrolled open-label study to analyze the efficacy and safety of IN for patients with UC.
Methods
Patients with moderate to severe active UC (clinical activity index [CAI] ≥ 8) took 2 g/day of IN for 52 weeks. CAI at weeks 0, 4, 8, and 52 and Mayo endoscopic subscore (MES) and Geboes score (GS) at weeks 0, 4, and 52 were assessed. Clinical remission (CAI ≤ 4), mucosal healing (MES ≤ 1), and histological healing (GS ≤ 1) rates at each assessment were evaluated. Overall adverse events (AEs) during study period were also evaluated. The impact of IN on mucosal microbial composition was assessed using 16S ribosomal RNA gene sequences.
Results
Thirty-three patients were enrolled. The rates of clinical remission at weeks 4, 8, and 52 were 67%, 76%, and 73%, respectively. The rates of mucosal healing at weeks 4 and 52 were 48% and 70%, respectively. AEs occurred in 17 patients (51.5%) during follow-up. Four patients (12.1%) showed severe AEs, among whom 3 manifested acute colitis. No significant alteration in the mucosal microbial composition was observed with IN treatment.
Conclusions
One-year treatment of moderate to severe UC with IN was effective. IN might be a promising therapeutic option for maintaining remission in UC, although the relatively high rate of AEs should be considered. -
Citations
Citations to this article as recorded by- Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis
Konstantinos Ouranos, Hira Saleem, Stephanos Vassilopoulos, Athanasios Vassilopoulos, Evangelia K Mylona, Fadi Shehadeh, Markos Kalligeros, Bincy P Abraham, Eleftherios Mylonakis
Inflammatory Bowel Diseases.2025; 31(1): 37. CrossRef - Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD
Monica Dzwonkowski, Janak Bahirwani, Samantha Rollins, Alicia Muratore, Vikram Christian, Yecheskel Schneider
Current Gastroenterology Reports.2025;[Epub] CrossRef - Indigo naturalis‑associated ischemic injury of colorectal mucosa: A case series study
Yiheng Ke, Liang Xu, Qi Tang, Zheyu Ruan, Junjie Liu, Shuiliang Ruan
Experimental and Therapeutic Medicine.2025;[Epub] CrossRef - Indigo naturalis (Qing dai) for inflammatory bowel disease: A systematic review and meta-analysis
Rinkalben Kakdiya, Daya Krishna Jha, Arup Choudhury, Anuraag Jena, Vishal Sharma
Clinics and Research in Hepatology and Gastroenterology.2024; 48(1): 102250. CrossRef - Reply to “Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis”
Akihito Yokote, Noriyuki Imazu, Junji Umeno, Keisuke Kawasaki, Shin Fujioka, Yuta Fuyuno, Yuichi Matsuno, Tomohiko Moriyama, Kohta Miyawaki, Koichi Akashi, Takanari Kitazono, Takehiro Torisu
Journal of Gastroenterology.2024; 59(1): 77. CrossRef - Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
Preetha Iyengar, Gala Godoy-Brewer, Isha Maniyar, Jacob White, Laura Maas, Alyssa M. Parian, Berkeley Limketkai
Nutrients.2024; 16(7): 934. CrossRef - Clinical Efficacy and Future Application of Indigo Naturalis in the Treatment of Ulcerative colitis
Dianzhen Wu, Qi Huang, Yingbi Xu, Ruiyi Cao, Ming Yang, Jin Xie, Dingkun Zhang
Journal of Ethnopharmacology.2024; : 118782. CrossRef - Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis
Akihito Yokote, Noriyuki Imazu, Junji Umeno, Keisuke Kawasaki, Shin Fujioka, Yuta Fuyuno, Yuichi Matsuno, Tomohiko Moriyama, Kohta Miyawaki, Koichi Akashi, Takanari Kitazono, Takehiro Torisu
Journal of Gastroenterology.2023; 58(9): 868. CrossRef - Hyaluronic acid/inulin-based nanocrystals with an optimized ratio of indigo and indirubin for combined ulcerative colitis therapy via immune and intestinal flora regulation
Jin Xie, Qi Huang, Huijuan Xie, Jun Liu, Shimin Tian, Ruiyi Cao, Ming Yang, Junzhi Lin, Li Han, Dingkun Zhang
International Journal of Biological Macromolecules.2023; 252: 126502. CrossRef - High-Quality Indigo Naturalis Obtained with Automatic Foam Separation
Xin Yang, Jun Tang, Juan Su, Xin Yang, Ming Yang, Xiangbo Yang, Qisen Ji, Yanan He, Li Han, Dingkun Zhang
ACS Applied Materials & Interfaces.2023; 15(37): 43272. CrossRef
- Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis
- 6,854 View
- 249 Download
- 7 Web of Science
- 10 Crossref
- IBD
- Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia
- Chenwen Cai, Juntao Lu, Lijie Lai, Dongjuan Song, Jun Shen, Jinlu Tong, Qing Zheng, Kaichun Wu, Jiaming Qian, Zhihua Ran
- Intest Res 2022;20(2):213-223. Published online April 29, 2022
- DOI: https://doi.org/10.5217/ir.2021.00031
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
The incidence and prevalence of inflammatory bowel disease (IBD) is rising in Asia recently. The study aimed to obtain a comprehensive understanding of the current status of drug therapy and monitoring for IBD in Asia.
Methods
A questionnaire investigation on drug therapy and monitoring for IBD was conducted right before the 6th Annual Meeting of Asian Organization for Crohn’s & Colitis. Questionnaires were provided to Asian physicians to fill out via emails between March and May 2018.
Results
In total, responses of 166 physicians from 129 medical centers were included for analysis. Among the surveyed regions, the most average number of IBD specialist gastroenterologists and nurses was 4.8 per center in Taiwan and 2.5 per center in Mainland China, respectively. 5-Aminosalicylic acid/sulfasalazine (99.4%) was the most preferred first-line choice for mild-moderate ulcerative colitis (UC), meanwhile corticosteroid (83.7%) was widely applied for severe UC. The first-line medication for Crohn’s disease (CD) markedly varied as corticosteroid (68.1%) was the most favored in Mainland China, Japan, and South Korea, followed by infliximab (52.4%) and azathioprine (47.0%). Step-up strategy was preferred in mild-moderate UC (96.4%), while 51.8% of the physicians selected top-down treatment for CD. Only 25.9% and 17.5% of the physicians could test blood concentration of infliximab and antibody to infliximab in their hospitals, respectively.
Conclusions
The current status of drug therapy and monitoring for IBD in Asia possesses commonalities as well as differences. Asian recommendations, IBD specialist teams and practice of therapeutic drug monitoring are required to improve IBD management in Asia. -
Citations
Citations to this article as recorded by- Expression and role of CTHRC1 in inflammatory bowel disease in children
Heng Tang, Xiang Gao, Zhaofang Wu, Jia Chen, Li Chen, Xiang Du
Cytotechnology.2025;[Epub] CrossRef - Importance of STAT3 signaling in preeclampsia (Review)
Daniela Marzioni, Federica Piani, Nicoletta Di Simone, Stefano Giannubilo, Andrea Ciavattini, Giovanni Tossetta
International Journal of Molecular Medicine.2025;[Epub] CrossRef - New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases
Jihye Park, I. Seul Park, Ji Hyung Kim, Jung Hyun Ji, Soo Jung Park, Jae Jun Park, Tae Il Kim, Seung Won Kim, Jae Hee Cheon
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef - Primary surgery versus pharmacotherapy for newly diagnosed ileocecal Crohn’s disease: a hospital-based cohort study
Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
The Korean Journal of Internal Medicine.2024; 39(5): 759. CrossRef - Signal detection and analysis of sulfasalazine adverse reaction events based on the US FDA adverse event reporting database
Yikuan Du, Lingzhi Zhang, Liang Shi, Zhuoming Guo, Ziyi Luo, Ye Zheng, Yu Zeng, Yin Huang, Jiawen Luo, Xiaochun Guo, Mianda Hu, Yuhong Chen, Jinfeng Zhu, Yi Liu, Chun Yang
Expert Opinion on Drug Safety.2024; : 1. CrossRef - Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data
Ryan C Ungaro, Harisha Kadali, Wenwen Zhang, Shashi Adsul, Walter Reinisch
Journal of Crohn's and Colitis.2023; 17(12): 1949. CrossRef
- Expression and role of CTHRC1 in inflammatory bowel disease in children
- 4,893 View
- 201 Download
- 3 Web of Science
- 6 Crossref
- IBD
- Efficacy and tolerability of hyperbaric oxygen therapy in small bowel stricturing Crohn’s disease: a pilot study
- Bhaskar Kante, Pabitra Sahu, Saurabh Kedia, Sudheer K. Vuyyuru, Kapil Soni, Maneesh Singhal, Raju Sharma, Govind Makharia, Vineet Ahuja
- Intest Res 2022;20(2):231-239. Published online February 8, 2022
- DOI: https://doi.org/10.5217/ir.2021.00056
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Existing therapeutic options for complicated Crohn’s disease (CD) like biologics and surgery are limited by inadequate long-term efficacy, cost, and adverse effects. Tissue hypoxia is important in CD pathogenesis and may be ameliorated with hyperbaric oxygen therapy (HBOT). We assessed the efficacy and tolerability of HBOT in small bowel stricturing CD.
Methods
This pilot study included patients of small bowel stricturing CD (from April 2019 to January 2020) who underwent HBOT. These patients were refractory to conventional medical treatment or had multiple strictures not amenable to resection. Each session of HBOT was given for 60 minutes with a pressure of 1.5–2.5 atm. Clinical, biochemical responses and Short Inflammatory Bowel Disease (SIBD) questionnaire were evaluated at 2 and 6 months, and radiological response was evaluated at 6 months.
Results
Fourteen patients (mean age, 42.9±15.7 years; male, 50%) were subjected to 168 HBOT sessions. Thirteen patients (92.7%) had strictures and 1 patient had enterocutaneous fistula in addition. Median number of HBOT sessions was 11 (range, 3–20) which were administered over a median of 4 weeks. Most patients tolerated it well except 1 who had hemotympanum. At 2 and 6 months of follow-up, 64.2% of patients had a clinical response, 50% and 64.2% of patients had clinical remission respectively. Steroid-free clinical remission was seen in 8 (57%) of patients with radiological improvement in 50%. There was a significant improvement in SIBD scores at 2-month follow-up (59.4 vs. 44.5, P=0.03).
Conclusions
HBOT can be a safe and effective therapeutic option in patients with stricturing small bowel CD refractory to conventional medical treatment. -
Citations
Citations to this article as recorded by- Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use
Jung Min Moon, Kyoung-Eun Kwon, Ju Won Lee, Kyung Rok Minn, Kyuwon Kim, Jeongkuk Seo, Seung Yong Shin, Sun-Young Jung, Chang Hwan Choi
Digestive and Liver Disease.2025; 57(1): 176. CrossRef - Hyperbaric oxygen therapy as a possible therapeutic candidate for sepsis-associated encephalopathy: A novel hypothesis
Sung Eun Lee, Eunjung Park, Ji-yun Kim, HyukHoon Kim
Medical Hypotheses.2024; 182: 111212. CrossRef - Treating paediatric Crohn’s disease is challenging but new treatments hold promise
Tina Nie
Drugs & Therapy Perspectives.2024; 40(3): 121. CrossRef - The Future of Advanced Therapies for Pediatric Crohn’s Disease
Julie Gallagher, Joel R. Rosh, Benjamin Sahn
Pediatric Drugs.2023; 25(6): 621. CrossRef - Role of hyperbaric oxygen therapy in patients with inflammatory bowel disease
Harpreet Kaur, Gursimran Singh Kochhar, Parambir S. Dulai
Current Opinion in Gastroenterology.2023; 39(4): 263. CrossRef
- Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use
- 6,189 View
- 303 Download
- 5 Web of Science
- 5 Crossref
- IBD
- Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
- Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa, Fabiana Zingone
- Intest Res 2022;20(1):114-123. Published online August 4, 2021
- DOI: https://doi.org/10.5217/ir.2021.00037
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Current literature is lacking in studies comparing the incidence of adverse events (AEs) in patients with inflammatory bowel diseases (IBD) treated with adalimumab (ADA) or vedolizumab (VDZ) in a real-life scenario. Therefore, our primary aim was to compare the AEs occurring in patients taking ADA to those of patients taking VDZ.
Methods
In this single center study, data on AEs from IBD patients who underwent treatment with ADA and VDZ were retrospectively collected. AE rates per 100 person-years were calculated. A Cox regression model was used to estimate the hazard ratios of the AEs between the 2 drugs.
Results
A total of 16 ADA patients (17.2%) and 11 VDZ patients (7.6%) had AEs causing drug interruption during the study period (P=0.02). Most of the AEs were noninfectious extraintestinal events (50% in ADA and 54.5% in VDZ) while infections accounted for 31.2% of the AEs in patients treated with ADA and 27.3% in those treated with VDZ. The incidence rate of AEs causing withdrawal of therapy was 13.2 per 100 person-years for ADA and 5.3 per 100 person-years for VDZ, corresponding to a 76% lower risk in patients in VDZ. Considering the first year of treatment, we observed 34 subjects treated with ADA (36.5%) having at least 1 AEs and 57 (39.3%) among those taking VDZ (P=0.67).
Conclusions
VDZ has a lower incidence rate of AEs causing withdrawal of treatment compared to ADA but a similar risk of AEs not causing drug interruption. Real-life head-to-head studies are still necessary to further explore the safety profile of these drugs. -
Citations
Citations to this article as recorded by- Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
Journal of Gastroenterology and Hepatology.2024; 39(3): 519. CrossRef - Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers
Sara Karlqvist, Michael C. Sachs, Carl Eriksson, Yang Cao, Scott Montgomery, Jonas F. Ludvigsson, Ola Olén, Jonas Halfvarson
American Journal of Gastroenterology.2024; 119(12): 2480. CrossRef - The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry
Nishaanth Dalavaye, Simon Erridge, Martha Nicholas, Manaswini Pillai, Lara Bapir, Carl Holvey, Ross Coomber, James J Rucker, Jonathan Hoare, Mikael H Sodergren
Expert Review of Gastroenterology & Hepatology.2023; 17(1): 85. CrossRef - Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intestinal Research.2023; 21(3): 353. CrossRef - Beyond the survey, to the ideal therapy for Asian
Ki Jae Jo, Jong Pil Im
Intestinal Research.2023; 21(3): 280. CrossRef - Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
Jihye Park
Intestinal Research.2022; 20(1): 1. CrossRef - Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn’s Disease: A Multicenter Observational Study
Jihye Park, Jaeyoung Chun, Hyuk Yoon, Jae Hee Cheon
Inflammatory Bowel Diseases.2022;[Epub] CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Journal of Clinical Medicine.2022; 11(14): 4202. CrossRef - Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
Gut and Liver.2022; 16(5): 764. CrossRef - Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
Sujin Choi, Eun Sil Kim, Yiyoung Kwon, Mi Jin Kim, Yon Ho Choe, Byung-Ho Choe, Ben Kang
Journal of Korean Medical Science.2022;[Epub] CrossRef
- Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
- 5,561 View
- 357 Download
- 11 Web of Science
- 11 Crossref
- IBD
- Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
- Anthony Buisson, Lisa Cannon, Konstantin Umanskiy, Roger D. Hurst, Neil H. Hyman, Atsushi Sakuraba, Joel Pekow, Sushila Dalal, Russell D. Cohen, Bruno Pereira, David T. Rubin
- Intest Res 2022;20(3):303-312. Published online August 4, 2021
- DOI: https://doi.org/10.5217/ir.2021.00018
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
We assessed the effectiveness of anti-TNF agents and its associated factors to prevent endoscopic and clinical postoperative recurrence (POR) in Crohn’s disease (CD).
Methods
From a prospectively-maintained database, we retrieved 316 CD patients who underwent intestinal resection (2011–2017). Endoscopic (Rutgeerts index ≥ i2 at 6 months) and clinical (recurrence of symptoms leading to hospitalization or therapeutic escalation) POR were assessed.
Results
In 117 anti-TNF-naïve patients, anti-TNF therapy was more effective than immunosuppressive agents (odds ratio [OR], 8.8; 95% confidence interval [CI], 1.8–43.9; P= 0.008) and no medication/5-aminosalicylates (OR, 5.2; 95% CI, 1.0–27.9; P= 0.05) to prevent endoscopic POR. In 199 patients exposed to anti-TNF prior to the surgery, combination with anti-TNF and immunosuppressive agents was more effective than anti-TNF monotherapy (OR, 2.32; 95% CI, 1.02–5.31; P= 0.046) to prevent endoscopic POR. Primary failure to anti-TNF agent prior to surgery was predictive of anti-TNF failure to prevent endoscopic POR (OR, 2.41; 95% CI, 1.10–5.32; P= 0.03). When endoscopic POR despite anti-TNF prophylactic medication (n = 55), optimizing anti-TNF and adding an immunosuppressive drug was the most effective option to prevent clinical POR (hazard ratio, 7.38; 95% CI, 1.54–35.30; P= 0.012). Anti-TNF therapy was the best option to prevent clinical POR (hazard ratio, 3.10; 95% CI, 1.09–8.83; P= 0.034) in patients with endoscopic POR who did not receive any biologic to prevent endoscopic POR (n = 55).
Conclusions
Anti-TNF was the most effective medication to prevent endoscopic and clinical POR. Combination with anti-TNF and immunosuppressive agents should be considered in patients previously exposed to anti-TNF. -
Citations
Citations to this article as recorded by- Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
Journal of Gastroenterology and Hepatology.2024; 39(3): 519. CrossRef - Postoperative small bowel Crohn's disease: how to diagnose, manage and treat
Chak Lam Ip, Ray Boyapati, Rahul Kalla
Current Opinion in Gastroenterology.2024; 40(3): 209. CrossRef - Stapled End-To-Side Ileocolic Anastomosis in Crohn’s Disease: Old Dog, Reliable Tricks? A Retrospective Two-Center Cohort Study
Volkan Doğru, Jean H. Ashburn, Umut Akova, Alton G. Sutter, Eren Esen, Emily M. Gardner, Andre da Luz Moreira, Arman Erkan, John Kirat, Michael J. Grieco, Feza H. Remzi
Annals of Surgery Open.2024; 5(1): e374. CrossRef - Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min
Yonsei Medical Journal.2024; 65(7): 380. CrossRef - How Reliable Is Endoscopic Scoring of Postoperative Recurrence in Crohn Disease?: A Systematic Review and Meta-Analysis
Eline M. L. van der Does de Willebois, Vittoria Bellato, Marjolijn Duijvestein, Susan van Dieren, Silvio Danese, Pierpaolo Sileri, Christianne J. Buskens, Andrea Vignali, Willem A. Bemelman
Annals of Surgery Open.2024; 5(1): e397. CrossRef - Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease
Michiel T. J. Bak, Karlijn Demers, Nassim Hammoudi, Matthieu Allez, Mark S. Silverberg, Gwenny M. Fuhler, Kaushal Parikh, Marieke J. Pierik, Laurents P. S. Stassen, C. Janneke van der Woude, Michail Doukas, Oddeke van Ruler, Annemarie C. de Vries
Alimentary Pharmacology & Therapeutics.2024; 60(3): 310. CrossRef - Common Mistakes in Managing Patients with Inflammatory Bowel Disease
Javier P. Gisbert, María Chaparro
Journal of Clinical Medicine.2024; 13(16): 4795. CrossRef - Preventing Recurrence of Crohn’s Disease Post-Ileocaecal Surgery in Paediatric Patients: A Therapy Guide Based on Systematic Review of the Evidence
Jiri Bronsky, Kristyna Zarubova, Michal Kubat, Vojtech Dotlacil
Pediatric Drugs.2024; 26(6): 659. CrossRef - Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Javier P. Gisbert, María Chaparro
Drugs.2023; 83(13): 1179. CrossRef - Prevention of postoperative recurrence in Crohn’s disease: the never-ending story
Jung-Bin Park, Sang Hyoung Park
Intestinal Research.2022; 20(3): 279. CrossRef - Timing of individualized surgical intervention in Crohn’s disease
Kai Xia, Ren-Yuan Gao, Xiao-Cai Wu, Lu Yin, Chun-Qiu Chen
World Journal of Gastrointestinal Surgery.2022; 14(12): 1320. CrossRef
- Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
- 4,857 View
- 535 Download
- 9 Web of Science
- 11 Crossref
Review
- Inflammatory bowel diseases
- Update of endoscopic management of Crohn’s disease strictures
- Akshay Pokala, Bo Shen
- Intest Res 2020;18(1):1-10. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.09158
-
Abstract
PDFPubReaderePub
- One of the most common complications of Crohn’s disease (CD) is the formation of strictures. Endoscopy plays a vital role not only in the diagnosis, differential diagnosis, and disease monitoring of CD, but also the delivery of effective treatment. The purpose of this review is to update the endoscopic management of strictures in CD. Endoscopic therapy has provided minimally invasive treatment for CD. Commonly used endoscopic treatment modalities include balloon dilation, endoscopic stricturotomy, endoscopic strictureplasty, and endoscopic stenting. The pros and cons of these endoscopic treatment modalities are discussed.
-
Citations
Citations to this article as recorded by- Increasing Rates of Bowel Resection Surgery for Stricturing Crohn’s Disease in the Biologic Era
Kush Fansiwala, Ellen J Spartz, Andrew R Roney, Mary R Kwaan, Jenny S Sauk, Po-Hung Chen, Berkeley N Limketkai
Inflammatory Bowel Diseases.2025; 31(4): 935. CrossRef - Altered gut microbiome-metabolite interactions link intestinal inflammation severity and MR enterography abnormalities in Crohn’s disease
Ruonan Zhang, Zhoulei Li, Li Huang, Weimiao Kong, Yidong Zheng, Yangdi Wang, Xiaodi Shen, Lili Huang, Xinyue Wang, Qingzhu Zheng, Luyao Wu, Yaoqi Ke, Ren Mao, Zhenpeng Peng, Canhui Sun, Shi-Ting Feng, Shaochun Lin, Yejun Wang, Xuehua Li
iScience.2025; 28(5): 112310. CrossRef - Clinical outcomes of serial endoscopic balloon dilation for duodenal Crohn’s disease-associated strictures
Juanjuan Zhang, Xiaoli Qian, Lin Zhu, Binlin Da, Xiaofan Zhao, Qin He, Lixin Wang, Yi Li, Zhiming Wang
Surgical Endoscopy.2024; 38(8): 4512. CrossRef - Endoscopic Management of Strictures in Crohn’s Disease: An Unsolved Case
Gaetano Coppola, Chiara Principessa, Federica Di Vincenzo, Pierluigi Puca, Angelo Del Gaudio, Ivan Capobianco, Bianca Bartocci, Alfredo Papa, Giovanni Cammarota, Loris Riccardo Lopetuso, Franco Scaldaferri
Journal of Clinical Medicine.2024; 13(16): 4842. CrossRef - The Promise of Single-Cell RNA Sequencing to Redefine the Understanding of Crohn’s Disease Fibrosis Mechanisms
Iona Campbell, Michael Glinka, Fadlo Shaban, Kathryn J. Kirkwood, Francesca Nadalin, David Adams, Irene Papatheodorou, Albert Burger, Richard A. Baldock, Mark J. Arends, Shahida Din
Journal of Clinical Medicine.2023; 12(12): 3884. CrossRef - How to Prevent and Treat the Most Frequent Adverse Events Related to Luminal Dilation and Stenting in Benign Disease
Eduardo Rodrigues-Pinto, Joel Ferreira-Silva, Peter D. Siersema
American Journal of Gastroenterology.2023; 118(9): 1521. CrossRef - Crohn's disease: an update
Ella Cockburn, Shahed Kamal, Andrea Chan, Vikram Rao, Tianwei Liu, Joanna Y Huang, Jonathan P Segal
Clinical Medicine.2023; 23(6): 549. CrossRef - Documento de posicionamiento. Recomendaciones del grupo español de trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre el tratamiento de la estenosis en la enfermedad de Crohn
Carme Loras, Miriam Mañosa, Xavier Andújar, Vicente Sánchiz, Marc Martí-Gallostra, Yamile Zabana, Ana Gutiérrez, Manuel Barreiro-de Acosta
Gastroenterología y Hepatología.2022; 45(4): 315. CrossRef - Endoscopic Balloon Dilation Is Cost-Effective for Crohn’s Disease Strictures
Kate E. Lee, Francesca Lim, Adam S. Faye, Bo Shen, Chin Hur
Digestive Diseases and Sciences.2022; 67(12): 5462. CrossRef - Position Statement. Recommendations of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn’s disease
Carme Loras, Miriam Mañosa, Xavier Andújar, Vicente Sánchiz, Marc Martí-Gallostra, Yamile Zabana, Ana Gutiérrez, Manuel Barreiro-de Acosta
Gastroenterología y Hepatología (English Edition).2022; 45(4): 315. CrossRef - Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice
Kyeong Ok Kim
Clinical Endoscopy.2022; 55(4): 480. CrossRef - Esophageal Manifestations of Dermatological Diseases, Diagnosis, and Management
Amr M. Arar, Kelli DeLay, David A. Leiman, Paul Menard-Katcher
Current Treatment Options in Gastroenterology.2022; 20(4): 513. CrossRef - Active Assessment of Inflammatory Bowel Disease
金良 肖
Advances in Clinical Medicine.2022; 12(12): 11023. CrossRef - Long-Term Outcome of Endoscopic Balloon Dilation for Duodenal Crohn’s Disease-Associated Strictures
Juanjuan Zhang, Yi Li, Yanqing Diao, Binlin Da, Zhiming Wang
Digestive Diseases and Sciences.2021; 66(10): 3570. CrossRef - Story of strictures, stents, and many more
Saiprasad Girish Lad, Kailash M. Kolhe, Shamshersingh G. Chauhan, Meghraj A. Ingle, Mayur Gattani, Harshad Khairnar
Gastrointestinal Endoscopy.2021; 93(2): 535. CrossRef - Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study
Seong Ran Jeon, Jin-Oh Kim, Jeong-Sik Byeon, Dong-Hoon Yang, Bong Min Ko, Hyeon Jeong Goong, Hyun Joo Jang, Soo Jung Park, Eun Ran Kim, Sung Noh Hong, Jong Pil Im, Seong-Eun Kim, Ja Seol Koo, Chang Soo Eun, Dong Kyung Chang
Gut and Liver.2021; 15(3): 375. CrossRef - Managing Stricturing Crohn's Disease: Resect? Strictureplasty? Dilate?
Lea Lowenfeld, Fabrizio Michelassi
Journal of Laparoendoscopic & Advanced Surgical Techniques.2021; 31(8): 881. CrossRef - Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef
- Increasing Rates of Bowel Resection Surgery for Stricturing Crohn’s Disease in the Biologic Era
- 9,144 View
- 295 Download
- 14 Web of Science
- 18 Crossref
Focused Reviews
- Colorectal neoplasia
- Nutritional issues in patients with cancer
- Duk Hwan Kim
- Intest Res 2019;17(4):455-462. Published online October 14, 2019
- DOI: https://doi.org/10.5217/ir.2019.00076
-
Abstract
PDFPubReaderePub
- Cancer is a catabolic inflammatory disease that causes patients to often experience weight loss, or even cachexia in severe cases. Undernourishment in patients with cancer impairs the quality of life and therapeutic response, further leading to poor prognosis. Active and frequent nutritional screening and assessment using valid tools are important for fast and appropriate nutritional intervention. Additionally, a suitable individualized nutritional intervention strategy should be established based on the nutritional assessment result. In general, nutritional intervention begins with nutritional counseling of patients diagnosed with cancer, and a well-planned nutritional counseling improves the treatment adherence and nutritional status. When planning nutritional supplementation for cancer patients, specific nutrients, including amino acids and fatty acids, should be considered. However, there has been no consistent result showing that any particular nutrient significantly improves the prognosis of cancer patients. Hence, continuous attention from clinical physicians is needed to plan nutritional improvement in patients with cancer.
-
Citations
Citations to this article as recorded by- Early identification of weight loss trajectories in advanced cancer and associations with survival
Sophia Fuller, Stacey Alexeeff, Bette Caan, Marcus D Goncalves, Richard F Dunne, Tobias Janowitz, Mariam Jamal-Hanjani, Tilak K Sundaresan, Elizabeth M Cespedes Feliciano
JNCI: Journal of the National Cancer Institute.2025;[Epub] CrossRef - Burden of malnutrition among cancer patients in Ethiopia: a systematic review and meta-analysis
Abdi Birhanu, Monas Kitessa, Usmael Jibro, Dawit Firdisa, Obsan Kassa, Jerman Dereje, Alemayehu Deresa, Nesredin Ahmed, Lamesa Abdissa, Shambel Nigussie, Magarsa Lami
BMC Public Health.2025;[Epub] CrossRef - Experiences of cancer patients in receiving dietary advice from healthcare professionals and of healthcare professionals in providing this advice—a systematic review
Laura Keaver, Niamh O’Callaghan, Amy E. LaVertu, Cherith J. Semple, Ciara M. Hughes, Jeffrey R. Hanna, Lisa Ryan
Journal of Cancer Survivorship.2024; 18(4): 1211. CrossRef - Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma
Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Shuai Zhang, Qingyun Cao, Xiaoxuan Xue, Hongmei Jing, Hui Liu
Cancer Medicine.2024;[Epub] CrossRef - Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
European Journal of Oncology Nursing.2024; 68: 102497. CrossRef - RETRACTED: Examining the relationship between nutritional status and wound healing in head and neck cancer treatment: A focus on malnutrition and nutrient deficiencies
Yajun Chen, Yuying Li, Yaqi Ceng, Chunlei Li, Yueying Li, Yujie Wang, Kun Wang
International Wound Journal.2024;[Epub] CrossRef - Anti-breast cancer activity of the essential oil from grapefruit mint (Mentha suaveolens × piperita)
Zohreh Jahanafrooz, Mir Mohammad Hossein Mousavi, Soghra Akbarzadeh, Maedeh Hemmatzadeh, Filippo Maggi, Mohammad Reza Morshedloo
Fitoterapia.2024; 174: 105875. CrossRef - Accompagnement alimentaire du cancéreux, lutte contre les dégoûts et aversions
Philippe Pouillart
Pratiques en nutrition.2024; 20(78): 14. CrossRef - Exome-Based Amino Acid Optimization: A Dietary Strategy to Satisfy Human Nutritional Demands and Enhance Muscle Strength in Breast Tumor Mice Undergoing Chemotherapy
Congcong Gong, Chunwei Jiao, Huijia Liang, Yuxin Ma, Qingping Wu, Yizhen Xie
Journal of Agricultural and Food Chemistry.2024; 72(13): 7089. CrossRef - Prehabilitation and its Outcomes in Cancer Patients: A Narrative Review
A. J. Rajendran, M. A. Raja, S. Benedic Kingslin Suresh
Indian Journal of Physical Medicine and Rehabilitation.2024; 34(1): 5. CrossRef - Nutritional Experiences and Perceptions of Breast Cancer Patients Receiving Chemotherapy: A Qualitative Study
Sema Koçan, Canan Altınsoy, Yağmur Demirel Özbek
Ordu Üniversitesi Hemşirelik Çalışmaları Dergisi.2024; 7(2): 358. CrossRef - Adopting a systems-thinking approach to optimise dietary and exercise referral practices for cancer survivors
Ria Joseph, Nicolas H. Hart, Natalie Bradford, Fiona Crawford-Williams, Matthew P. Wallen, Reegan Knowles, Chad Y. Han, Vivienne Milch, Justin J. Holland, Raymond J. Chan
Supportive Care in Cancer.2024;[Epub] CrossRef - Thoracic CT imaging in obesity: Technical challenges, imaging findings and future outlook
Perawish Suwathep, Alexander Sheeka, Susan Copley
Meta-Radiology.2024; 2(3): 100100. CrossRef - Evaluating the Outcomes in Patients with Colorectal Cancer Using the Malnutrition Universal Screening Tool: A Systematic Review
Calin Muntean, Andiana Roxana Blidari, Alaviana Monique Faur, Razvan Ovidiu Curca, Catalin Vladut Ionut Feier
Journal of Multidisciplinary Healthcare.2024; Volume 17: 4277. CrossRef - Poor nutrition doubles post-COVID-19 syndrome risk in cancer patients: insights from a Chinese multicentre study
Liangyuan Zhang, Haihang Yu, Jianzhou Yang, Rila Su, Jiaqi Zhang, Rongbiao Zeng, Yajie Liu, Lei Zhang, Junjie Xu
Frontiers in Nutrition.2024;[Epub] CrossRef - Effects of Five-Step Nutritional Interventions Conducted by a Multidisciplinary Care Team on Gastroenteric Cancer Patients Undergoing Chemotherapy: A Randomized Clinical Trial
Lijia Chen, Minyan Zhao, Liping Tan, Yusong Zhang
Nutrition and Cancer.2023; 75(1): 197. CrossRef - Effectiveness of mHealth diet interventions in cancer survivors: A systematic review and meta-analysis of randomized controlled trials
Yabo Gong, Xiaohan Jiang, Xijie Chen, Shi Chen, Yuee Wen, Xiuhong Yuan, Jiamin Chen, Junsheng Peng
Asia-Pacific Journal of Oncology Nursing.2023; 10(3): 100196. CrossRef - Mapping the global research landscape on nutritional support for patients with gastrointestinal malignancy: visualization analysis
Muna Shakhshir, Amani S. Abushanab, Amer Koni, Abdelkarim Barqawi, Khaled Demyati, Samah W. Al-Jabi, Sa’ed H. Zyoud
Supportive Care in Cancer.2023;[Epub] CrossRef - Prognostic significance of controlling nutritional status score for patients with gastric cancer: A systematic review and meta‑analysis
Jian Yin, Jin Qu, Xiaoxiao Liang, Meimei Wang
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef - Web-based nutrition: a useful resource for cancer patients?
Diana Elena Lazar, Roxana Postolica, Bianca Hanganu, Veronica Mocanu, Beatrice Gabriela Ioan
Frontiers in Nutrition.2023;[Epub] CrossRef - Depression and Anxiety Mediate the Associations between Nutritional Status, Functional Capacity, and Quality of Life in Patients with Cancer
Iliana Evangelou, Konstantina Vamvakari, Ioanna Panagiota Kalafati, Michail Kipouros, Arezina N. Kasti, Rena I. Kosti, Fotini Bonoti, Odysseas Androutsos
Nutrition and Cancer.2023; 75(9): 1783. CrossRef - Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study
Enrique Grande, Fernando Moreno, José Trigo, Jaume Capdevila, Jimena Abilés, Mariola Sirvent, Margarita Garrido-Siles, Gabriel Olveira, Julia Ocón, Maria Luisa Fernández Soto
Supportive Care in Cancer.2023;[Epub] CrossRef - Anti-Cancer Properties of Flaxseed Proteome
Yulia Merkher, Elizaveta Kontareva, Anastasia Alexandrova, Rajesha Javaraiah, Margarita Pustovalova, Sergey Leonov
Proteomes.2023; 11(4): 37. CrossRef - Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors
Salvatore Artale, Sabrina Barzaghi, Nunziata Grillo, Claudia Maggi, Stefano Lepori, Chiara Butti, Antonella Bovio, Lucia Barbarini, Andrea Colombo, Laura Zanlorenzi, Elena Castiglioni, Alessandra Trojani
Nutrition and Cancer.2022; 74(1): 2. CrossRef - Chronic Inflammation in Obesity and Cancer Cachexia
Rosa Divella, Gennaro Gadaleta Caldarola, Antonio Mazzocca
Journal of Clinical Medicine.2022; 11(8): 2191. CrossRef - A Nutrition and Inflammation-Related Nomogram to Predict Overall Survival in Surgically Resected Esophageal Squamous Cell Carcinoma (ESCC) Patients
Juan Li, Xinyu Mei, Di Sun, Mingfa Guo, Mingran Xie, Xia Chen
Nutrition and Cancer.2022; 74(5): 1625. CrossRef - Diet and exercise advice and referrals for cancer survivors: an integrative review of medical and nursing perspectives
Ria Joseph, Nicolas H. Hart, Natalie Bradford, Oluwaseyifunmi Andi Agbejule, Bogda Koczwara, Alexandre Chan, Matthew P. Wallen, Raymond J. Chan
Supportive Care in Cancer.2022; 30(10): 8429. CrossRef - MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review)
Xin Li, Lidong Du, Qiang Liu, Zhong Lu
Experimental and Therapeutic Medicine.2022;[Epub] CrossRef - Nutritional risk screening in malignant tumors: a study of 375 cancer inpatients
Min Zhang, Yuying Guo, Xiaodi Zhang, Yu Zhang, Yuanyuan Fan, Yanting Liu, Kelei Zhao, Ruijuan Fan, Ping Lu
Supportive Care in Cancer.2022; 30(10): 8333. CrossRef - Prognostic Value of the Pre-Treatment Prognostic Nutritional Index for Patients with Unresectable Locally-Advanced and Advanced Stage Upper Gastrointestinal Tract Cancer
Chaichana Chantharakhit, Nantapa Sujaritvanichpong, Chanachai Chantharakhit
International Journal of General Medicine.2022; Volume 15: 6681. CrossRef - Visceral fat area and albumin based nutrition-related prognostic index model could better stratify the prognosis of diffuse large B-cell lymphoma in rituximab era
Ziyuan Shen, Lingling Hu, Shuo Zhang, Qian Sun, Weidong Li, Dongmei Yan, Guoqi Cai, Wei Sang
Frontiers in Nutrition.2022;[Epub] CrossRef - Malnutrition induced by cancer and oncology treatment
Jelena Kostadinović, Jelena Kotur-Stevuljević, Nevena Ivanović, Zoran Andrić
Hrana i ishrana.2022; 63(1): 9. CrossRef - Irish cancer patients and survivors have a positive view of the role of nutritional care in cancer management from diagnosis through survivorship
Laura Keaver
Irish Journal of Medical Science (1971 -).2021; 190(4): 1387. CrossRef - Nutrition intervention is beneficial to the quality of life of patients with gastrointestinal cancer undergoing chemotherapy in Vietnam
Linh Thuy Nguyen, Anh Kim Dang, Phuong Thi Duong, Hanh Bich Thi Phan, Chinh Tuyet Thi Pham, Anh Tuan Le Nguyen, Huong Thi Le
Cancer Medicine.2021; 10(5): 1668. CrossRef - Managing the effects of cancer and cancer treatments on patients’ nutritional status
Kathell Margaret Geraghty
Nursing Standard.2021; 36(3): 54. CrossRef - Overcoming Disparities in Cancer: A Need for Meaningful Reform for Hispanic and Latino Cancer Survivors
Joshua P. Kronenfeld, Kristi D. Graves, Frank J. Penedo, Betina Yanez
The Oncologist.2021; 26(6): 443. CrossRef - Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?
Dana A. M. Mustafa, Lawlaw Saida, Diba Latifi, Leonoor V. Wismans, Willem de Koning, Lona Zeneyedpour, Theo M. Luider, Bernadette van den Hoogen, Casper H. J. van Eijck
Cancers.2021; 13(12): 2896. CrossRef - Detection of Lung Cancer via Blood Plasma and 1H-NMR Metabolomics: Validation by a Semi-Targeted and Quantitative Approach Using a Protein-Binding Competitor
Elien Derveaux, Michiel Thomeer, Liesbet Mesotten, Gunter Reekmans, Peter Adriaensens
Metabolites.2021; 11(8): 537. CrossRef - Short Nutritional Assessment Questionnaire as a predictor of undernutrition in cancer patients receiving outpatient chemotherapy: A retrospective study
Kiyomi Harada, Masami Okagaki, Hiroko Neriya, Kengo Yoshii, Keiko Sekido, Akane Higashi
European Journal of Oncology Nursing.2021; 54: 102013. CrossRef - A Quasi-Experimental Study of the Effect of Ginger Tea on Preventing Nausea and Vomiting in Patients With Gynecological Cancers Receiving Cisplatin-Based Regimens
Dhuha Y. Wazqar, Hala A. Thabet, Amany M. Safwat
Cancer Nursing.2021; 44(6): E513. CrossRef - Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials
Elwira Gliwska, Dominika Guzek, Zuzanna Przekop, Jacek Sobocki, Dominika Głąbska
Nutrients.2021; 13(12): 4551. CrossRef - Nutritional Status of Patients with Nasopharyngeal Carcinoma
Yussy Afriani Dewi, Arief Fakhrizal, Shinta Fitri Boesoirie, Ayu Hardianti Saputri
Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1435. CrossRef - Bilayer Mucoadhesive Buccal Film for Mucosal Ulcers Treatment: Development, Characterization, and Single Study Case
Thais F. R. Alves, Alesssandra C. Rios, Katiusca da Silva Pontes, Decio L. Portella, Norberto Aranha, Patricia Severino, Eliana B. Souto, Joyce K. M. Gonsalves, Rogeria de Souza Nunes, Marco V. Chaud
Pharmaceutics.2020; 12(7): 657. CrossRef - A Study on Challenges to Health Care Delivery Faced by Cancer Patients in India During the COVID-19 Pandemic
Manasij Mitra, Maitraye Basu
Journal of Primary Care & Community Health.2020;[Epub] CrossRef - Enteral feed based gradual improvement of body mass index and normalization of micronutrients in children with malnutrition
Meryem KEÇELİ BAŞARAN, Nur ZENGIN, Ali DOĞAN, Alihan SURSAL, Fatih OZDENER
Journal of Surgery and Medicine.2020; 4(9): 826. CrossRef - Quality of Life (QoL) of cancer patients and its association with nutritional and performance status: A pilot study
Mohammad Morshad Alam, Tania Rahman, Zinia Afroz, Promit Ananyo Chakraborty, Abrar Wahab, Sanjana Zaman, Mohammad Delwer Hossain Hawlader
Heliyon.2020; 6(10): e05250. CrossRef - Altered Preoperative Nutritional Status in Colorectal Cancer: A Not So Infrequent Issue
Javier Páramo-Zunzunegui, Araceli Ramos-Carrasco, Marcos Alonso-García, Rosa Cuberes-Montserrat, Gil Rodríguez-Caravaca, Manuel Durán-Poveda, María Ximena Silveyra
Journal of Nutrition and Metabolism.2020; 2020: 1. CrossRef - Impact of Early Incorporation of Nutrition Interventions as a Component of Cancer Therapy in Adults: A Review
Julie Richards, Mary Beth Arensberg, Sara Thomas, Kirk W. Kerr, Refaat Hegazi, Michael Bastasch
Nutrients.2020; 12(11): 3403. CrossRef
- Early identification of weight loss trajectories in advanced cancer and associations with survival
- 10,058 View
- 382 Download
- 43 Web of Science
- 48 Crossref
- Microbiota
- Importance of nutritional therapy in the management of intestinal diseases: beyond energy and nutrient supply
- Seong-Eun Kim
- Intest Res 2019;17(4):443-454. Published online September 4, 2019
- DOI: https://doi.org/10.5217/ir.2019.00075
-
Abstract
PDFPubReaderePub
- The gut is an immune-microbiome-epithelial complex. Gut microbiome-host interactions have widespread biological implications, and the role of this complex system extends beyond the digestion of food and nutrient absorption. Dietary nutrients can affect this complex and play a key role in determining gut homeostasis to maintain host health. In this article, we review various dietary nutrients and their contribution to the pathogenesis and treatment of various intestinal diseases including inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, and diverticulitis, among other such disorders. A better understanding of diet-host-gut microbiome interactions is essential to provide beneficial nutrients for gut health and to limit nutritional hazards to ensure successful nutritional management of gastrointestinal conditions in clinical practice.
-
Citations
Citations to this article as recorded by- Capsule robots for the monitoring, diagnosis, and treatment of intestinal diseases
Xiangyu Wei, Peipei Xi, Minjie Chen, Ya Wen, Hao Wu, Li Wang, Yujuan Zhu, Yile Ren, Zhifeng Gu
Materials Today Bio.2024; 29: 101294. CrossRef - TOPICAL ISSUES OF NUTRITION OF PATIENTS WITH DISEASES OF THE GASTROINTESTINAL TRACT
Nikishina S.S.
"Medical & pharmaceutical journal "Pulse".2023; : 17. CrossRef - An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intestinal Research.2023; 21(2): 189. CrossRef - Rectal swabs are a reliable method of assessing the colonic microbiome
Greg Turner, Michael O’Grady, Daniel Hudson, Xochitl Morgan, Frank Frizelle, Rachel Purcell
International Journal of Medical Microbiology.2022; 312(2): 151549. CrossRef - Detection of Colistin Sulfate on Piglet Gastrointestinal Tract Microbiome Alterations
Shulin Fu, Yuzhen Yuan, Xinyue Tian, Linglu Zhou, Ling Guo, Dan Zhang, Jing He, Chun Peng, Yinsheng Qiu, Chun Ye, Yu Liu, Bingbing Zong
Veterinary Sciences.2022; 9(12): 666. CrossRef - The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1. CrossRef - EFFECTS OF ADOLESCENTS' NUTRITION ON THEIR QUALITY OF LIFE
Filina I.A., Nikishina S.S., Kulakova A.S.
"Medical & pharmaceutical journal "Pulse".2021; : 13. CrossRef - Faecal Microbiota Microsphere Contributed to Relieving Gut Barrier Damage in Colitis
Shuang Zhen, Cheng Zhao, Xin Zhao, Wu Ji, Jieshou Li
Macromolecular Research.2020; 28(6): 644. CrossRef - Dysregulation of gut microbiome is linked to disease activity of rheumatic diseases
Yanfeng Bao, Chen Dong, Juan Ji, Zhifeng Gu
Clinical Rheumatology.2020; 39(9): 2523. CrossRef
- Capsule robots for the monitoring, diagnosis, and treatment of intestinal diseases
- 10,031 View
- 410 Download
- 8 Web of Science
- 9 Crossref
Original Articles
- Inflammatory bowel diseases
- Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
- Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
- Intest Res 2019;17(3):340-348. Published online May 31, 2019
- DOI: https://doi.org/10.5217/ir.2019.00012
-
Abstract
PDFPubReaderePub
- Background/Aims
Ustekinumab is effective in active Crohn’s disease. In a retrospective study we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not always reflect the average “real world” patient cohort, we assessed weather patients who would not have qualified for approval studies show similar outcomes.
Methods
Forty-one patients with mild to severe active Crohn’s disease were treated with ustekinumab (intravenous 6 mg per kg/body weight) followed by subcutaneous ustekinumab (90 mg) at week 8. Depending on the clinical response maintenance therapy was chosen every 8 or 12 weeks. Clinical response was defined by Crohn’s Disease Activity Index (CDAI) decline, decline of stool frequency or clinical improvement. Inclusion criteria for approval studies were assessed.
Results
The 58.5% (24/41) showed clinical response to ustekinumab. The 58.3% of this group (14/24) achieved clinical remission. Clinical response correlated significantly with drop of stool frequency and improvement of CDAI score. The 39 out of 41 patients had no side effects and we observed no serious infections. About a third of our patients would not have met ustekinumab approval study criteria. However, patients who did not meet study criteria showed clinical improvement numerically in the same range compared to patients who would have qualified for approval studies.
Conclusions
Ustekinumab is effective, safe and well tolerated in a highly therapy refractory patient cohort. Even though a reasonable number of patients did not meet ustekinumab approval study criteria, approval study results seem to be representative to the overall patient cohort. -
Citations
Citations to this article as recorded by- Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis
Yaqing Bai, Yinghao Sun, Qi He, Xiaoyin Bai, Hong Yang
European Journal of Gastroenterology & Hepatology.2024; 36(4): 359. CrossRef - Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef - Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Sailish Honap, Susanna Meade, Hajir Ibraheim, Peter M. Irving, Michael P. Jones, Mark A. Samaan
Digestive Diseases and Sciences.2022; 67(3): 1018. CrossRef - Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases
Hongsheng Yang, Bingyang Li, Qin Guo, Jian Tang, Bo Peng, Ni Ding, Miao Li, Qingfang Yang, Zicheng Huang, Na Diao, Xia Zhu, Jun Deng, Huili Guo, Pinjin Hu, Kang Chao, Xiang Gao
Alimentary Pharmacology & Therapeutics.2022; 55(7): 764. CrossRef - Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature
Jordi Sarto, Berta Caballol, Joan Berenguer, Iban Aldecoa, Álvaro Carbayo, Daniel Santana, Ivan Archilla, Carles Gaig, Francesc Graus, Julián Panés, Albert Saiz
Therapeutic Advances in Neurological Disorders.2022;[Epub] CrossRef - Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis
Mohammed Assem Khorshid, Ahmed Cordie, Sherief Abd-Elsalam
Journal of Coloproctology.2022; 42(02): 178. CrossRef - Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Journal of Clinical Medicine.2022; 11(14): 4202. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn’s disease (PROSE): a 16-week follow-up
Anders Forss, Mark Clements, Pär Myrelid, Hans Strid, Charlotte Söderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olén, Jonas F. Ludvigsson, Jonas Halfvarson
Scandinavian Journal of Gastroenterology.2021; 56(6): 680. CrossRef - Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
Seungwon Yang, Siyoung Yang, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi, Jae Hee Cheon, Yun Mi Yu
Therapeutic Advances in Chronic Disease.2021;[Epub] CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Eficacia y seguridad de ustekinumab en la práctica clínica real. Estudio multicéntrico retrospectivo. Cohorte ARAINF
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino
Gastroenterología y Hepatología.2020; 43(3): 126. CrossRef - Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone, Ambrogio Orlando
Expert Opinion on Biological Therapy.2020; 20(2): 193. CrossRef - Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino
Gastroenterología y Hepatología (English Edition).2020; 43(3): 126. CrossRef - Ustekinumab en enfermedad de Crohn: efectividad y seguridad en práctica clínica
Cristina Saldaña Dueñas, María Rullán Iriarte, Alfonso Elosua González, Cristina Rodríguez Gutiérrez, Saioa Rubio Iturria, Óscar Nantes Castillejo
Gastroenterología y Hepatología.2020; 43(9): 497. CrossRef - Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Marisa Iborra, Belén Beltrán, Agnes Fernández‐Clotet, Eva Iglesias‐Flores, Pablo Navarro, Montserrat Rivero, Ana Gutiérrez, Mónica Sierra‐Ausin, Francisco Mesonero, Rocío Ferreiro‐Iglesias, Joaquín Hinojosa, Xavier Calvet, Beatriz Sicilia, Carlos González
Alimentary Pharmacology & Therapeutics.2020; 52(6): 1017. CrossRef - Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
Clas-Göran af Björkesten, Tuire Ilus, Taru Hallinen, Erkki Soini, Anja Eberl, Kalle Hakala, Mikko Heikura, Airi Jussila, Ritva Koskela, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Urpo Nieminen, Heikki Nuutinen, Markku Heikkinen, Ulla-Maija Suhonen
European Journal of Gastroenterology & Hepatology.2020; 32(12): 1507. CrossRef - Ustekinumab in Crohn's disease: Effectiveness and safety in clinical practice
Cristina Saldaña Dueñas, María Rullán Iriarte, Alfonso Elosua González, Cristina Rodríguez Gutiérrez, Saioa Rubio Iturria, Óscar Nantes Castillejo
Gastroenterología y Hepatología (English Edition).2020; 43(9): 497. CrossRef - Editorial: real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease—results from the ENEIDA registry. Authors' reply
Marisa Iborra, Belén Beltrán, Pilar Nos
Alimentary Pharmacology & Therapeutics.2019; 50(5): 600. CrossRef
- Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis
- 8,448 View
- 274 Download
- 15 Web of Science
- 19 Crossref
- Inflammatory bowel diseases
- Risk of surgery in patients with stricturing type of Crohn’s disease at the initial diagnosis: a single center experience
- Yuji Maehata, Yutaka Nagata, Tomohiko Moriyama, Yuichi Matsuno, Atsushi Hirano, Junji Umeno, Takehiro Torisu, Tatsuya Manabe, Takanari Kitazono, Motohiro Esaki
- Intest Res 2019;17(3):357-364. Published online February 21, 2019
- DOI: https://doi.org/10.5217/ir.2018.00107
-
Abstract
PDFPubReaderePub
- Background/Aims
It remains uncertain which patients with stricturing-type Crohn’s disease (CD) require early small bowel surgery after the initial diagnosis. We aimed to clarify clinical characteristics associated with the intervention in such condition of CD.
Methods
We retrospectively evaluated the clinical course of 53 patients with CD and small bowel strictures who were initially treated with medications after the initial diagnosis. We investigated possible associations between small bowel surgery and the following: clinical factors and radiologic findings at initial diagnosis and the types of medications administered during follow-up.
Results
Twenty-eight patients (53%) required small bowel resection during a median follow-up period of 5.0 years (range, 0.5–14.3 years). The cumulative incidence rates of small bowel surgery at 2, 5, and 10 years were 26.4%, 41.0%, and 63.2%, respectively. Univariate analysis indicated that obstructive symptoms (P=0.036), long-segment stricture (P<0.0001), and prestenotic dilation (P<0.0001) on radiography were associated with small bowel surgery, and immunomodulatory (P=0.037) and biological therapy (P=0.008) were significant factors during follow-up. Multivariate analysis revealed that long-segment stricture (hazard ratio [HR], 4.25; 95% confidence interval [CI], 1.78–10.53; P=0.001) and prestenotic dilation (HR, 3.41; 95% CI, 1.24–9.62; P=0.018) on radiography showed a positive correlation with small bowel surgery, and biological therapy (HR, 0.40; 95% CI, 0.15–0.99; P=0.048) showed a negative correlation.
Conclusions
CD patients with long-segment stricture and prestenotic dilation on radiography seem to be at a higher risk of needing small bowel surgery. For such patients, early surgical intervention might be appropriate, even at initial diagnosis. -
Citations
Citations to this article as recorded by- Colonic strictures in Crohn’s disease: a non-surgical survival
Sarra Laabidi, Hamed Aboubecrine, Salma Souissi, Donia Gouiaa, Asma Labidi, Nadia Ben Mustapha, Anis Haddad, Amine Sebai, Meriem Serghini, Monia Fekih, Hanene Jaziri, Jalel Boubaker
Future Science OA.2025;[Epub] CrossRef - Comprehensive review and update of stricturing Crohn’s disease
Alexander T. Elford, Zaid Ardalan, Paul Simkin, Britt Christensen
Indian Journal of Gastroenterology.2024; 43(1): 64. CrossRef - A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice
Dominik Bettenworth, Mark E. Baker, Joel G. Fletcher, Vipul Jairath, Cathy Lu, Willem Bemelman, Geert d’Haens, Andre d’Hoore, Axel Dignass, Iris Dotan, Roger Feakins, Phillip Fleshner, Christina Ha, Gaylyn Henderson, Ruishen Lyu, Julian Panes, Gerhard Rog
Nature Reviews Gastroenterology & Hepatology.2024; 21(8): 572. CrossRef - Reliability of MR Enterography Features for Describing Fibrostenosing Crohn Disease
Florian Rieder, Mark E. Baker, David H. Bruining, Jeff L. Fidler, Eric C. Ehman, Shannon P. Sheedy, Jay P. Heiken, Justin M. Ream, David R. Holmes, Akitoshi Inoue, Payam Mohammadinejad, Yong S. Lee, Stuart A. Taylor, Jaap Stoker, Guangyong Zou, Zhongya Wa
Radiology.2024;[Epub] CrossRef - Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease
Florian Rieder, Christopher Ma, Jurij Hanzel, Joel G. Fletcher, Mark E. Baker, Zhongya Wang, Leonardo Guizzetti, Lisa M. Shackelton, Julie Rémillard, Mihir Patel, Jiafei Niu, Ronald Ottichilo, Cynthia S. Santillan, Nunzia Capozzi, Stuart A. Taylor, David
Radiology.2024;[Epub] CrossRef - Use of oral diet and nutrition support in management of stricturing and fistulizing Crohn's disease
Kush Fansiwala, Neha D. Shah, Kelly A. McNulty, Mary R. Kwaan, Berkeley N. Limketkai
Nutrition in Clinical Practice.2023; 38(6): 1282. CrossRef - Sarcopenia hinders the decline in disease activity after surgery for people with Crohn's disease: Preliminary results
Asuka Yasueda, Yuki Sekido, Takashi Takeda, Takayuki Ogino, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi, Tsunekazu Mizushima
Nutrition.2022; 94: 111526. CrossRef - Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review
Julien D Schulberg, Emily K Wright, Bronte A Holt, Helen E Wilding, Amy L Hamilton, Alyson L Ross, Michael A Kamm
Journal of Gastroenterology and Hepatology.2021; 36(2): 344. CrossRef - Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Gut and Liver.2021; 15(1): 92. CrossRef - Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease
Muaad Abdulla, Thean Soon Chew
Current Opinion in Gastroenterology.2021; 37(3): 275. CrossRef - Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
Sudheer K. Vuyyuru, Bhaskar Kante, Peeyush Kumar, Pabitra Sahu, Saurabh Kedia, Mukesh Kumar Ranjan, Raju Sharma, Rajesh Panwar, Govind Makharia, Vineet Ahuja
Scientific Reports.2021;[Epub] CrossRef - Inpatient Management of Inflammatory Bowel Disease-Related Complications
Manreet Kaur, Robin L. Dalal, Seth Shaffer, David A. Schwartz, David T. Rubin
Clinical Gastroenterology and Hepatology.2020; 18(6): 1346. CrossRef - Surgical treatment of intestinal stricture in inflammatory bowel disease
Helen M. Mohan, John C. Coffey
Journal of Digestive Diseases.2020; 21(6): 355. CrossRef
- Colonic strictures in Crohn’s disease: a non-surgical survival
- 7,489 View
- 185 Download
- 13 Web of Science
- 13 Crossref
Case Reports
- Fecal microbiota transplantation for refractory Crohn's disease
- Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho
- Intest Res 2017;15(2):244-248. Published online April 27, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.2.244
-
Abstract
PDFPubReaderePub
Approximately one-third of patients with Crohn's disease do not respond to conventional treatments, and some experience significant adverse effects, such as serious infections and lymphoma, and many patients require surgery due to complications. Increasing evidence suggests that specific changes in the composition of gut microbiota, termed as dysbiosis, are a common feature in patients with inflammatory bowel disease (IBD). Dysbiosis can lead to activation of the mucosal immune system, resulting in chronic inflammation and the development of mucosal lesions. Recently, fecal microbiota transplantation, aimed at modifying the composition of gut microbiota to overcome dysbiosis, has become a potential alternative therapeutic option for IBD. Herein, we present a patient with Crohn's colitis in whom biologic therapy failed previously, but clinical remission and endoscopic improvement was achieved after a single fecal microbiota transplantation infusion.
-
Citations
Citations to this article as recorded by- Epigenetics and the role of nutraceuticals in health and disease
Amr El-Sayed, Lotfi Aleya, Mohamed Kamel
Environmental Science and Pollution Research.2023; 30(11): 28480. CrossRef - Crohn’s disease: Etiology, pathogenesis and treatment strategies
Izel Aycan BASOGLU, Berna KARAKOYUN
Marmara Medical Journal.2023; 36(2): 249. CrossRef - Alteration of microbiota antibody‐mediated immune selection contributes to dysbiosis in inflammatory bowel diseases
Eva Michaud, Louis Waeckel, Rémi Gayet, Roman Goguyer‐Deschaumes, Blandine Chanut, Fabienne Jospin, Katell Bathany, Magali Monnoye, Coraline Genet, Amelie Prier, Caroline Tokarski, Philippe Gérard, Xavier Roblin, Nicolas Rochereau, Stéphane Paul
EMBO Molecular Medicine.2022;[Epub] CrossRef - Gut microbiota: A new target for T2DM prevention and treatment
Lulu Liu, Jiheng Zhang, Yi Cheng, Meng Zhu, Zhifeng Xiao, Guangcong Ruan, Yanling Wei
Frontiers in Endocrinology.2022;[Epub] CrossRef - Current Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Cátia Almeida, Rita Oliveira, Pilar Baylina, Rúben Fernandes, Fábio G. Teixeira, Pedro Barata
Biomedicines.2022; 10(11): 2742. CrossRef - Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021
Fengwei Zhang, Peilin Yang, Yilin Chen, Ruirui Wang, Baocheng Liu, Jianying Wang, Min Yuan, Lei Zhang
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef - Fecal microbiota transplantation for Crohn’s disease: a systematic review and meta-analysis
F. Cheng, Z. Huang, W. Wei, Z. Li
Techniques in Coloproctology.2021; 25(5): 495. CrossRef - Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Sahil Khanna
Intestinal Research.2021; 19(3): 265. CrossRef - Microbiota and epigenetics: promising therapeutic approaches?
Amr El-Sayed, Lotfi Aleya, Mohamed Kamel
Environmental Science and Pollution Research.2021; 28(36): 49343. CrossRef - Improving the Gut Microbiota with Probiotics and Faecal Microbiota Transplantation
Yogita M. Patil, Rajashree B. Patwardhan, Pragati S. Abhyankar
Journal of Pure and Applied Microbiology.2021; 15(3): 1111. CrossRef - Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome
Yonghyun Lee, Nobuhiko Kamada, James J. Moon
Advanced Drug Delivery Reviews.2021; 179: 114021. CrossRef - Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview
Donghun Oh, Keun-Ah Cheon
Journal of the Korean Academy of Child and Adolescent Psychiatry.2020; 31(3): 131. CrossRef - Development of the Korean Form of the Premonitory Urge for Tics Scale: A Reliability and Validity Study
Mira Kim, Sang-Keun Chung, Jong-Chul Yang, Jong-Il Park, Seok Hyun Nam, Tae Won Park
Journal of the Korean Academy of Child and Adolescent Psychiatry.2020; 31(3): 146. CrossRef - Secondary causes of inflammatory bowel diseases
Yezaz A Ghouri, Veysel Tahan, Bo Shen
World Journal of Gastroenterology.2020; 26(28): 3998. CrossRef - Fecal microbiota transplantation in the treatment of Crohn disease
Miranda Collins, Morgan DeWitt
JAAPA.2020; 33(9): 34. CrossRef - Inflammatory Bowel Diseases: The Role of Gut Microbiota
Cristiana De Musis, Lucia Granata, Marcello Dallio, Agnese Miranda, Antonietta G. Gravina, Marco Romano
Current Pharmaceutical Design.2020; 26(25): 2951. CrossRef - The human-microbiome superorganism and its modulation to restore health
E. Salvucci
International Journal of Food Sciences and Nutrition.2019; 70(7): 781. CrossRef - The microbiome, cancer, and cancer therapy
Beth A. Helmink, M. A. Wadud Khan, Amanda Hermann, Vancheswaran Gopalakrishnan, Jennifer A. Wargo
Nature Medicine.2019; 25(3): 377. CrossRef - RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef - Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery
Michael Kriss, Keith Z Hazleton, Nichole M Nusbacher, Casey G Martin, Catherine A Lozupone
Current Opinion in Microbiology.2018; 44: 34. CrossRef - Microbiota transplantation: concept, methodology and strategy for its modernization
Faming Zhang, Bota Cui, Xingxiang He, Yuqiang Nie, Kaichun Wu, Daiming Fan
Protein & Cell.2018; 9(5): 462. CrossRef - The hygiene hypothesis at a glance: Early exposures, immune mechanism and novel therapies
Gabriel M. Alexandre-Silva, Pablo A. Brito-Souza, Ana C.S. Oliveira, Felipe A. Cerni, Umberto Zottich, Manuela B. Pucca
Acta Tropica.2018; 188: 16. CrossRef - The Safety of Fecal Microbiota Transplantation for Crohn’s Disease: Findings from A Long-Term Study
Honggang Wang, Bota Cui, Qianqian Li, Xiao Ding, Pan Li, Ting Zhang, Xiaozhong Yang, Guozhong Ji, Faming Zhang
Advances in Therapy.2018; 35(11): 1935. CrossRef - Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun
Intestinal Research.2017; 15(2): 145. CrossRef - Diagnosis and treatment of Crohn's disease
Hyun-Soo Kim
Journal of the Korean Medical Association.2017; 60(6): 484. CrossRef
- Epigenetics and the role of nutraceuticals in health and disease
- 6,645 View
- 64 Download
- 24 Web of Science
- 25 Crossref
-
Refractory
Clostridium difficile Infection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient - Mi-Ok Jang, Jun Hwan An, Sook-In Jung, Kyung-Hwa Park
- Intest Res 2015;13(1):80-84. Published online January 29, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.1.80
-
Abstract
PDFPubReader
The rates and severity of
Clostridium difficile infections, including pseudomembranous colitis, have increased markedly. However, there are few effective treatments for refractory or recurrentC. difficile infections and the outcomes are poor. Fecal microbiota transplantation is becoming increasingly accepted as an effective and safe intervention in patients with recurrent disease, likely due to the restoration of a disrupted microbiome. Cure rates of >90% are being consistently reported from multiple centers. We cured a case of severe refractoryC. difficile infection with fecal microbiota transplantation in a patient colonized by vancomycin-resistant enterococcus.-
Citations
Citations to this article as recorded by- The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
Rohma Ghani, Benjamin H. Mullish, Lauren A. Roberts, Frances J. Davies, Julian R. Marchesi
Gut Microbes.2022;[Epub] CrossRef - Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile
Mariachiara Mengoli, Monica Barone, Marco Fabbrini, Federica D’Amico, Patrizia Brigidi, Silvia Turroni
Genes.2022; 13(12): 2200. CrossRef - Colonization Dynamics of Multidrug-Resistant Klebsiella pneumoniae Are Dictated by Microbiota-Cluster Group Behavior over Individual Antibiotic Susceptibility: A Metataxonomic Analysis
János Juhász, Balázs Ligeti, Márió Gajdács, Nóra Makra, Eszter Ostorházi, Ferenc Balázs Farkas, Balázs Stercz, Ákos Tóth, Judit Domokos, Sándor Pongor, Dóra Szabó
Antibiotics.2021; 10(3): 268. CrossRef - Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis
Catherine M Cappetto
American Journal of Health-System Pharmacy.2021; 78(15): 1374. CrossRef - Fecal microbiota transplantation for antibiotic resistant bacteria decolonization
Sophie Amrane, Jean-Christophe Lagier
Human Microbiome Journal.2020; 16: 100071. CrossRef - Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a systematic review and meta-analysis
V. Tavoukjian
Journal of Hospital Infection.2019; 102(2): 174. CrossRef - Fifty shades of graft: How to improve the efficacy of faecal microbiota transplantation for decolonization of antibiotic-resistant bacteria
Benjamin Davido, Rui Batista, Aurélien Dinh, Pierre de Truchis, E.M. Terveer, Bruce Roberts, Ed J. Kuijper, Silvia Caballero
International Journal of Antimicrobial Agents.2019; 53(5): 553. CrossRef - RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef - Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review
S. Saha, R. Tariq, P.K. Tosh, D.S. Pardi, S. Khanna
Clinical Microbiology and Infection.2019; 25(8): 958. CrossRef - Gut Microbiota Modulation for Multidrug-Resistant Organism Decolonization: Present and Future Perspectives
Livia Gargiullo, Federica Del Chierico, Patrizia D’Argenio, Lorenza Putignani
Frontiers in Microbiology.2019;[Epub] CrossRef - Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection
Young Kyung Yoon, Jin Woong Suh, Eun-Ji Kang, Jeong Yeon Kim
Annals of Medicine.2019; 51(7-8): 379. CrossRef - The Role of Fecal Microbiota Transplantation in Reducing Intestinal Colonization With Antibiotic-Resistant Organisms: The Current Landscape and Future Directions
Michael H Woodworth, Mary K Hayden, Vincent B Young, Jennie H Kwon
Open Forum Infectious Diseases.2019;[Epub] CrossRef - Design and application of oral colon administration system
Hao Cheng, Shiyu Huang, Gangliang Huang
Journal of Enzyme Inhibition and Medicinal Chemistry.2019; 34(1): 1590. CrossRef - The Intestinal Microbiota as a Reservoir and a Therapeutic Target to Fight Multi-Drug-Resistant Bacteria: A Narrative Review of the Literature
Andrea Aira, Csaba Fehér, Elisa Rubio, Alex Soriano
Infectious Diseases and Therapy.2019; 8(4): 469. CrossRef - Intestinal microbiota and antibiotic resistance: Perspectives and solutions
Climent Casals-Pascual, Andrea Vergara, Jordi Vila
Human Microbiome Journal.2018; 9: 11. CrossRef - The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms
Srinivasa Nithin Gopalsamy, Michael H. Woodworth, Tiffany Wang, Cynthia T. Carpentieri, Nirja Mehta, Rachel J. Friedman-Moraco, Aneesh K. Mehta, Christian P. Larsen, Colleen S. Kraft
The American Journal of the Medical Sciences.2018; 356(5): 433. CrossRef - Mechanisms of antimicrobial resistance among hospital-associated pathogens
Ayesha Khan, William R. Miller, Cesar A. Arias
Expert Review of Anti-infective Therapy.2018; 16(4): 269. CrossRef - The commensal microbiota exacerbate infectious colitis in stressor-exposed mice
Jeffrey D. Galley, Nicola M. Parry, Brian M.M. Ahmer, James G. Fox, Michael T. Bailey
Brain, Behavior, and Immunity.2017; 60: 44. CrossRef - Microbial approaches for targeting antibiotic‐resistant bacteria
Wing Fei Wong, Marina Santiago
Microbial Biotechnology.2017; 10(5): 1047. CrossRef - Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
Erik R. Dubberke, Kathleen M. Mullane, Dale N. Gerding, Christine H. Lee, Thomas J. Louie, Harriet Guthertz, Courtney Jones
Open Forum Infectious Diseases.2016;[Epub] CrossRef - Can Fecal Microbiota Transplantation (FMT) Eradicate Fecal Colonization With Vancomycin-Resistant Enterococci (VRE)?
Kyung Mok Sohn, Shinhye Cheon, Yeon-Sook Kim
Infection Control & Hospital Epidemiology.2016; 37(12): 1519. CrossRef - Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
Hyun Ho Choi, Young-Seok Cho
Clinical Endoscopy.2016; 49(3): 257. CrossRef
- The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
- 5,922 View
- 44 Download
- 24 Web of Science
- 22 Crossref
First
Prev
